
CAS 1103522-45-7
:Aprocitentan
Description:
Aprocitentan is a chemical compound classified as an endothelin receptor antagonist, specifically targeting the endothelin-1 receptor. It is primarily investigated for its potential therapeutic applications in treating conditions such as resistant hypertension and heart failure. The compound works by blocking the action of endothelin-1, a potent vasoconstrictor, thereby promoting vasodilation and reducing blood pressure. Aprocitentan is characterized by its high selectivity for the endothelin receptors, which contributes to its efficacy and safety profile. The molecular structure of Aprocitentan includes specific functional groups that facilitate its interaction with the receptor sites. In clinical studies, it has shown promise in improving cardiovascular outcomes, although its long-term effects and safety are still under evaluation. As with many pharmacological agents, potential side effects may include hypotension, fluid retention, and electrolyte imbalances, necessitating careful monitoring during treatment. Overall, Aprocitentan represents a significant advancement in the management of hypertension and related cardiovascular disorders.
- Act-132577
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 9 products.
Despropyl Macitentan (N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]sulfamide)
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFormula:C16H14Br2N6O4SColor and Shape:Off-White SolidMolecular weight:543.9164Ref: IN-DA008TD9
1gTo inquire1mg157.00€5mg161.00€10mg191.00€25mg240.00€50mg602.00€100mgTo inquire250mgTo inquireN-Despropyl Macitentan (Aprocitentan)
CAS:Formula:C16H14Br2N6O4SColor and Shape:White To Off-White SolidMolecular weight:546.20Aprocitentan
CAS:<p>Aprocitentan (ACT-132577) is ETA and ETB antagonist .</p>Formula:C16H14Br2N6O4SPurity:99.17%Color and Shape:SolidMolecular weight:546.19N-Despropyl-macitentan
CAS:Controlled Product<p>Applications N-Despropyl-macitentan, is an active metabolite which is part of a family of endothelin receptor antagonist that allows for treatment of pulmonary arterial hypertension (PAH)<br>References Atsmon, J., et al.: Clin. Pharmacokinet., 525, 685 (2013); Sidharta, P.N., et al.: Clin. Drug Invest. (2014)<br></p>Formula:C16H14Br2N6O4SColor and Shape:NeatMolecular weight:546.19Aprocitentan
CAS:<p>Apcitentan is a vasoactive drug that belongs to the group of endothelin receptor antagonists. It is used in the treatment of erectile dysfunction and pulmonary hypertension. Apcitentan inhibits the angiotensin system, which includes angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). This inhibition increases the levels of endothelin and dopamine β-hydroxylase, thereby decreasing blood pressure. Apcitentan has been shown to increase glomerular filtration rate and reduce proteinuria in patients with chronic kidney disease. In vivo studies have shown that apcitentan is rapidly absorbed from the gastrointestinal tract, reaching peak concentrations within one hour. The pharmacodynamics of apcitentan are characterized by an inhibitory effect on pde5. Pharmacokinetic studies have found that apcitentan is metabolized by CYP</p>Formula:C16H14Br2N6O4SPurity:Min. 95%Molecular weight:546.19 g/mol









